secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001367644-23-000075
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions eliminates Chief Strategy role; 2022 bonuses slashed below target
--------------------------------------------------------------------------------

- Atul Saran departed as Chief Strategy Officer on March 17, 2023; receives severance per plan and RSU acceleration.
- 2022 NEO bonuses reduced due to below-target performance: CEO at 25%, others at 50% of target.
- Actual annual incentives for NEOs ranged from 25% to 58% of target.
- 2023 base salaries set: CEO $1,032,500 (120% bonus target); CFO $615,000; COO/GC $585,000 each.
- 2023 equity grants limited by share availability; PSUs tied to cumulative revenue and Adjusted EBITDA Margin over 2023-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000075/0001367644-23-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000075/ebs-20230323.htm
  HTML page:      https://secwatch.observer/filing/0001367644-23-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer